Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.85 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.85 |
| ▸ | SRC | P12931 | 3/20 | 0.63 |
| ▸ | STK4 | Q13043 | 2/20 | 0.63 |
| ▸ | STK25 | O00506 | 1/20 | 0.63 |
| ▸ | CIT | O14578 | 1/20 | 0.63 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.63 |
| ▸ | GAK | O14976 | 1/20 | 0.63 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.63 |
| ▸ | JAK2 | O60674 | 1/20 | 0.63 |
| ▸ | STK17B | O94768 | 1/20 | 0.63 |
| ▸ | STK10 | O94804 | 1/20 | 0.63 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.63 |
| ▸ | ABL1 | P00519 | 1/20 | 0.63 |
| ▸ | LCK | P06239 | 1/20 | 0.63 |
| ▸ | FYN | P06241 | 1/20 | 0.63 |
| ▸ | FES | P07332 | 1/20 | 0.63 |
| ▸ | CSF1R | P07333 | 1/20 | 0.63 |
| ▸ | YES1 | P07947 | 1/20 | 0.63 |
| ▸ | LYN | P07948 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2052299 | 0.99 | EGFR (0.84) | EGFRERBB2SRCSTK4STK25 | |
| SCHEMBL6383515 | 0.92 | EGFR (1.00) | EGFRERBB2SRCSTK4STK25 | |
| SCHEMBL1896455 | 0.90 | EGFR (0.85) | EGFRERBB2SRCMAP2K1 | |
| SCHEMBL3600034 | 0.90 | EGFR (0.72) | EGFRERBB2SRC | |
| SCHEMBL2023939 | 0.90 | EGFR (0.69) | EGFRERBB2SRC | |
| SCHEMBL14135437 | 0.90 | EGFR (0.68) | EGFRERBB2SRCSTK4 | |
| Hydrochloric Acid SCHEMBL2840495 | 0.90 | EGFR (0.83) | EGFRERBB2SRCMAP2K1 | |
| Hydrochloric Acid SCHEMBL2843055 | 0.90 | EGFR (0.83) | EGFRERBB2SRCMAP2K1 | |
| SCHEMBL28547159 | 0.89 | STK4 (0.70) | EGFRERBB2SRCSTK4MAP2K1 | |
| Hydrochloric Acid SCHEMBL13505731 | 0.89 | EGFR (0.68) | EGFRERBB2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116206-A1 | QUINOLINE DERIVATIVES USED AS PET IMAGING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2013-05-09 | — | — | US | claimed |
| EP-2516403-A1 | QUINOLINE DERIVATIVES USED AS PET IMAGING AGENTS | Imperial Innovations Limited (GB) | 2012-10-31 | — | — | EP | claimed |
| US-RE41084-E1 | Antineoplastic combinations | WYETH (US) | 2010-01-19 | — | — | US | claimed |
| US-20090325877-A1 | Combination Product of Receptor Tyrosine Kinase Inhibitor and Fatty Acid Synthase Inhibitor for Treating Cancer | WYETH (US) | 2009-12-31 | — | — | US | claimed |
| WO-2009151910-A2 | COMBINATION PRODUCT OF RECEPTOR TYROSINE KINASE INHIBITOR AND FATTY ACID SYNTHASE INHIBITOR FOR TREATING CANCER | WYETH (US) | 2009-12-17 | — | — | WO | claimed |
| US-20090105247-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2009-04-23 | — | — | US | claimed |
| US-7488754-B2 | Method for the treatment of polycystic kidney disease | WYETH (US) | 2009-02-10 | — | — | US | claimed |
| US-20080161575-A1 | Process for the synthesis of 6-amino-4-(3-chloro-4-fluorophenylamino)-7-ethoxyquinoline-3-carbonitrile | WYETH (US) | 2008-07-03 | — | — | US | claimed |
| US-RE40418-E1 | Treatment of neoplasms with CCI-779/EKB-569 combination | WYETH (US) | 2008-07-01 | — | — | US | claimed |
| EP-1871371-A2 | USE OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR (EGFR) IN GEFITINIB RESISTANT PATIENTS | Wyeth (US) | 2008-01-02 | — | — | EP | claimed |
| WO-2004032909-A2 | STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING BASIC EXCIPIENTS | WYETH HOLDINGS CORPORATION (US) | 2004-04-22 | — | — | WO | claimed |
| US-20040063672-A1 | Method for the treatment of polycystic kidney disease | WYETH HOLDINGS CORPORATION | 2004-04-01 | — | — | US | claimed |
| JP-2003526686-A | — | — | 2003-09-09 | — | — | JP | claimed |
| EP-1263503-A2 | USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS | AMERICAN CYANAMID COMPANY (US) | 2002-12-11 | — | — | EP | claimed |
| WO-2002083112-A2 | METHOD FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE | WYETH HOLDINGS CORPORATION (US) | 2002-10-24 | — | — | WO | claimed |
| US-6432979-B1 | ADMINISTERING SYNERGISTIC MIXTURE OF NON-STEROIDAL ANTIINFLAMMATORY AGENT AND EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR COMPRISING 3-CYANOQUINOLINE DERIVATIVE | AMERICAN CYANAMID COMPANY | 2002-08-13 | — | — | US | claimed |
| EP-1202746-A1 | NSAID AND EFGR KINASE INHIBITOR CONTAINING COMPOSITION FOR THE TREATMENT OR INHIBITION OF COLONIC POLYPS AND COLORECTAL CANCER | American Cyanamid Company (US) | 2002-05-08 | — | — | EP | claimed |
| US-6384051-B1 | ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY | 2002-05-07 | — | — | US | claimed |
| WO-2001068186-A2 | USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS | AMERICAN CYANAMID COMPANY (US) | 2001-09-20 | — | — | WO | claimed |
| WO-2001012227-A1 | NSAID AND EFGR KINASE INHIBITOR CONTAINING COMPOSITION FOR THE TREATMENT OR INHIBITION OF COLONIC POLYPS AND COLORECTAL CANCER | AMERICAN CYANAMID COMPANY (US) | 2001-02-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063672-A1 | Method for the treatment of polycystic kidney disease | PKD1, PKD2, PCSK6 | EGFR 11/4885ERBB2 122/4885SRC 1269/4885 |
| US-20130116206-A1 | QUINOLINE DERIVATIVES USED AS PET IMAGING AGENTS | ERBB2, EGFR, ERBB4 | EGFR 2/4885ERBB2 1/4885SRC 51/4885 |
| US-20080161575-A1 | Process for the synthesis of 6-amino-4-(3-chloro-4-fluorophenylamino)-7-ethoxyquinoline-3-carbonitrile | QPCT, CYP3A4, CPNE4 | EGFR 2586/4885ERBB2 1303/4885SRC 2831/4885 |
| US-20090325877-A1 | Combination Product of Receptor Tyrosine Kinase Inhibitor and Fatty Acid Synthase Inhibitor for Treating Cancer | FASN, FRS2, FGFR1 | EGFR 20/4885ERBB2 8/4885SRC 9/4885 |
| US-20090105247-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | ABL1, MAP3K7, MAP3K5 | EGFR 621/4885ERBB2 170/4885SRC 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.